SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Findings are among nine Decipher-focused abstracts being presented at annual conference “We look forward to the presentation of important new data examining the role of adverse molecular features in ...
SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...
Guggenheim notes that NCCN guidelines for prostate cancer V3.2026 were released and include updates to the principles of risk stratification and biomarkers sections. The principles of risk ...
Leveraging Electronic Health Record Tools and Social Work to Improve Advance Care Planning Documentation in Older Adults With Cancer Their investigation was a study imbedded in a randomized trial ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback